Baxter International | BAX - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Abbott USD 6.65B 787M 2026-06
AngioDynamics USD 44.78M 2.93M 2025-09
Artivion USD 73.14M 1.25M 2025-12
AtriCure USD 109.31M 3.97M 2026-03
Baxter International USD 1.14B 251M 2026-06
Becton, Dickinson and Co. USD 2.32B 161M 2026-06
Boston Scientific USD 3.82B 210M 2026-06
Cooper Companies USD 735.4M 40.2M 2026-03
Dexcom USD 750.3M 42.4M 2026-03
Edwards Lifesciences USD 1.35B 62.6M 2026-06
Fresenius EUR 1.55B 16M 2026-06
Globus Medical USD 548.17M 51.91M 2026-06
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
ICU Medical USD 235.05M 28.83M 2026-06
Inogen USD 41.34M 1.39M 2024-09
Insulet USD 562.6M 21.8M 2026-06
Integra LifeSciences USD 215.97M 2.77M 2026-06
Intuitive Surgical USD 2.02B 193.4M 2026-06
J&J USD 18.55B 1.31B 2026-06
Laboratory Of America USD 1.11B 98.2M 2026-06
Medtronic USD 6.01B 595M 2026-03
Merit Medical Systems USD 215.17M 30.37M 2026-06
Quest Diagnostics USD 906M 33M 2026-03
Smith & Nephew USD 2.09B 117M 2025-12
Stryker USD 4.5B 688M 2026-06
Tandem Diabetes Care USD 144.78M 7.99M 2026-06
Teleflex USD 331.71M 24.28M 2026-06
Terumo JPY 178.54B 29.52B 2026-06
Zimmer Biomet Holdings USD 1.36B 149.4M 2026-06